Literature DB >> 15063225

Predictive factors for survival in surgically resected clinical IA peripheral adenocarcinoma of the lung.

Yukinori Sakao1, Takahiko Nakazono, Toru Sakuragi, Masafumi Natsuaki, Tsuyoshi Itoh.   

Abstract

BACKGROUND: Patients with clinical IA (C-IA) lung cancer have a 5-year survival rate of approximately 70% after surgical therapy alone. We attempted to clarify preoperative factors that are predictive for poor prognosis after surgery among patients diagnosed with C-IA adenocarcinoma of the lung.
METHODS: Between 1994 and April 2002, 65 patients with C-IA adenocarcinoma of the lung underwent lobectomy + hilar and mediastinal node dissection. The chest computed tomography (CT) imaging and clinicopathologic records of the patients were examined. Tumors were subtyped into solid type or nonsolid type categories according to the component of ground glass opacity assessed by CT. Age, sex, serum carcinoembryonic antigen (CEA) level, histologic subtype (replacing versus nonreplacing), and tumor size were also analyzed.
RESULTS: Solid type on CT and high serum CEA level (>or=4.0 ng/mL) were prognostic factors for poor outcome in univariate analyses (p < 0.05). Solid type on CT, high serum CEA level, and larger tumor size (> 20 mm) were significant (p < 0.05) prognostic factors for poor outcome in multivariate analyses. Solid type on CT and high serum CEA level were significant (p < 0.01) risk factors for lymph node involvement in both univariate and multivariate analyses. Furthermore, based on the factors of CT subtype, tumor size, and serum CEA level, the 5-year disease-free survival rate was 20.1% for patients with two of the three factors, and 21.2% even if they were assessed as pN0. Computed tomography subtype was strongly associated with histologic subtype (p < 0.0001).
CONCLUSIONS: Solid type on CT (associated with histologic subtype such as nonreplacing type), tumor size larger than 20 mm, and high serum CEA concentration are important preoperative predictive factors for poor outcome after surgery for patients with C-IA lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063225     DOI: 10.1016/j.athoracsur.2003.09.055

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  14 in total

1.  Video-assisted thoracoscopic surgery versus open lobectomy for stage I lung cancer: A meta-analysis of long-term outcomes.

Authors:  Zhengjun Li; Hongxu Liu; LE Li
Journal:  Exp Ther Med       Date:  2012-02-13       Impact factor: 2.447

Review 2.  Controversies on lung cancers manifesting as part-solid nodules.

Authors:  Rowena Yip; Kunwei Li; Li Liu; Dongming Xu; Kathleen Tam; David F Yankelevitz; Emanuela Taioli; Betsy Becker; Claudia I Henschke
Journal:  Eur Radiol       Date:  2017-08-23       Impact factor: 5.315

Review 3.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

4.  Accuracy of CT parameters for assessment of tumour size and aggressiveness in lung adenocarcinoma with bronchoalveolar elements.

Authors:  U N Bhure; D Lardinois; V Kalff; T F Hany; A Soltermann; B Seifert; H C Steinert
Journal:  Br J Radiol       Date:  2010-10       Impact factor: 3.039

5.  Clinical characteristics of a second small nodule(s) associated with cT1-2N0M0 non-small-cell lung cancer.

Authors:  Ho Il Yoon; Jae-Jun Yim; Choon-Taek Lee; Young Whan Kim; Sung Koo Han; Young-Soo Shim; Young Tae Kim; Sook Whan Sung; Joo Hyun Kim; Chul-Gyu Yoo
Journal:  Lung       Date:  2006 Sep-Oct       Impact factor: 2.584

6.  Survival prediction of stage I lung adenocarcinomas by expression of 10 genes.

Authors:  Fabrizio Bianchi; Paolo Nuciforo; Manuela Vecchi; Loris Bernard; Laura Tizzoni; Antonio Marchetti; Fiamma Buttitta; Lara Felicioni; Francesco Nicassio; Pier Paolo Di Fiore
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

7.  Combined evaluation of preoperative FDG uptake on PET, ground-glass opacity area on CT, and serum CEA level: identification of both low and high risk of recurrence in patients with resected T1 lung adenocarcinoma.

Authors:  Kotaro Higashi; Tsutomu Sakuma; Kengo Ito; Seiji Niho; Yoshimichi Ueda; Takeshi Kobayashi; Ryuzo Sekiguchi; Tomoko Takahashi; Takashi Kato; Hisao Tonami
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-18       Impact factor: 9.236

Review 8.  Small peripheral lung adenocarcinoma: CT and histopathologic characteristics and prognostic implications.

Authors:  Zhi-gang Chu; Zhi-gang Yang; Heng Shao; Zhi-yu Zhu; Wen Deng; Shi-si Tang; Jing Chen; Yuan Li
Journal:  Cancer Imaging       Date:  2011-12-28       Impact factor: 3.909

9.  Prognostic significance of tumor size of small lung adenocarcinomas evaluated with mediastinal window settings on computed tomography.

Authors:  Yukinori Sakao; Hiroaki Kuroda; Mingyon Mun; Hirofumi Uehara; Noriko Motoi; Yuichi Ishikawa; Ken Nakagawa; Sakae Okumura
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

10.  Recent advances in the tumour biology of the GPI-anchored carcinoembryonic antigen family members CEACAM5 and CEACAM6.

Authors:  C H F Chan; C P Stanners
Journal:  Curr Oncol       Date:  2007-04       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.